The DNA damage response: Implications for tumor responses to radiation and chemotherapy

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 129-143

  Goldstein, Michael ^a   Kastan, Michael B ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer resistance; chemosensitization; DNA repair; radiosensitization; synthetic lethality

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; DNA CROSS LINKING AGENT; DNA METHYLATING AGENT; DNA TOPOISOMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CHEMORADIOTHERAPY; DNA DAMAGE; DNA DAMAGE RESPONSE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; HUMAN; IONIZING RADIATION; LETHALITY; MISMATCH REPAIR; PRIORITY JOURNAL; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; DNA METHYLATION; DRUG EFFECTS; GENETICS; NEOPLASMS; RADIATION RESPONSE; RADIOTHERAPY;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; HUMANS; NEOPLASMS; RADIOTHERAPY;

EID: 84921373620     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-081313-121208     Document Type: Article

References (100)

1. Shiloh Y. 1997. Ataxia-Telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. Annu. Rev. Genet. 31:635-62
2. Huen MS, Sy SM, Chen J. 2010. BRCA1 and its toolbox for the maintenance of genome integrity. Nat. Rev. Mol. Cell Biol. 11:138-48
3. Modrich P, Lahue R. 1996. Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annu. Rev. Biochem. 65:101-33
4. Luch A. 2005. Nature and nurture-lessons from chemical carcinogenesis. Nat. Rev. Cancer 5:113-25
5. Ciccia A, Elledge SJ. 2010. The DNA damage response: making it safe to play with knives. Mol. Cell 40:179-204
6. Bakkenist CJ, Kastan MB. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421:499-506
7. Kitagawa R, Bakkenist CJ, McKinnon PJ, Kastan MB. 2004. Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. Genes Dev. 18:1423-38
8. Kastan MB, Bartek J. 2004. Cell-cycle checkpoints and cancer. Nature 432:316-23
9. Byun TS, PacekM, Yee MC, et al. 2005. Functional uncoupling ofMCMhelicase and DNA polymerase activities activates the ATR-dependent checkpoint. Genes Dev. 19:1040-52
10. Brown EJ, BaltimoreD. 2000.ATRdisruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 14:397-402
11. Brown EJ, Baltimore D. 2003. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev. 17:615-28
12. Cromie GA, Connelly JC, Leach DR. 2001. Recombination at double-strand breaks and DNA ends: conserved mechanisms from phage to humans. Mol. Cell 8:1163-74
13. Leber R, Wise TW, Mizuta R, Meek K. 1998. The XRCC4 gene product is a target for and interacts with the DNA-dependent protein kinase. J. Biol. Chem. 273:1794-801
14. Christmann M, Tomicic MT, Roos WP, Kaina B. 2003. Mechanisms of human DNA repair: an update. Toxicology 193:3-34
15. GoldsteinM, Derheimer FA, Tait-Mulder J, KastanMB. 2013. Nucleolin mediates nucleosome disruption critical for DNA double-strand break repair. Proc. Natl. Acad. Sci. USA 110:16874-79
16. Mimitou EP, Symington LS. 2008. Sae2, Exo1 and Sgs1 collaborate in DNA double-strand break processing. Nature 455:770-74
17. Cadet J, Delatour T, DoukiT, et al. 1999. Hydroxyl radicals andDNAbase damage. Mutat. Res. 424:9-21
18. Nikjoo H, Uehara S, Wilson WE, et al. 1998. Track structure in radiation biology: theory and applications. Int. J. Radiat. Biol. 73:355-64
19. Rothkamm K, Lobrich M. 2003. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc. Natl. Acad. Sci. USA 100:5057-62
20. Willems P, Claes K, Baeyens A, et al. 2008. Polymorphisms in nonhomologous end-joining genes associated with breast cancer risk and chromosomal radiosensitivity. Genes Chromosomes Cancer 47:137-48
21. Lee MN, Tseng RC, Hsu HS, et al. 2007. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin. Cancer Res. 13:832-38
22. Esteller M, Silva JM, Dominguez G, et al. 2000. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl. Cancer Inst. 92:564-69
23. Ernestos B, Nikolaos P, Koulis G, et al. 2010. Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay. Int. J. Radiat. Oncol. Biol. Phys. 76:1199-205
24. FourquetA, Stoppa-LyonnetD, KirovaYM, et al. 2009. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status. Am. J. Clin. Oncol. 32:127-31
25. Jazayeri A, Falck J, Lukas C, et al. 2006. ATM-And cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat. Cell Biol. 8:37-45
26. Rainey MD, Charlton ME, Stanton RV, Kastan MB. 2008. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 68:7466-74
27. Biddlestone-Thorpe L, Sajjad M, Rosenberg E, et al. 2013. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin. Cancer Res. 19:3189-200
28. Hickson I, Zhao Y, Richardson CJ, et al. 2004. Identification and characterization of a novel and specific inhibitor of the ataxia-Telangiectasia mutated kinase ATM. Cancer Res. 64:9152-59
29. Westphal CH, Hoyes KP, Canman CE, et al. 1998. Loss of ATM radiosensitizes multiple p53 null tissues. Cancer Res. 58:5637-39
30. Veuger SJ, Curtin NJ, Richardson CJ, et al. 2003. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. 63:6008-15
31. Takata M, Sasaki MS, Sonoda E, et al. 1998. Homologous recombination and non-homologous endjoining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J. 17:5497-508
32. Konstantinidou G, Bey EA, Rabellino A, et al. 2009. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 69:7644-52
33. Mukherjee B, Tomimatsu N, AmancherlaK, et al. 2012. The dual PI3K/mTOR inhibitorNVP-BEZ235 is a potent inhibitor of ATM-And DNA-PKCs-mediated DNA damage responses. Neoplasia 14:34-43
34. Toledo LI, Murga M, Zur R, et al. 2011. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-Associated mutations. Nat. Struct. Mol. Biol. 18:721-27
35. Tao Y, LeteurC, Yang C, et al. 2009. Radiosensitization byChir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle 8:1196-205
36. Shao RG, Cao CX, Shimizu T, et al. 1997. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. 57:4029-35
37. Takai H, Naka K, Okada Y, et al. 2002. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J. 21:5195-205
38. Engelke CG, Parsels LA, Qian Y, et al. 2013. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776. Clin. Cancer Res. 19:4412-21
39. Herring CJ, West CM, Wilks DP, et al. 1998. Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers. Br. J. Cancer 78:1128-33
40. Robertson KA, Bullock HA, Xu Y, et al. 2001. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res. 61:2220-25
41. Taverna P, Hwang HS, Schupp JE, et al. 2003. Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. Cancer Res. 63:838-46
42. Liu SK, Coackley C, Krause M, et al. 2008. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother. Oncol. 88:258-68
43. Dungey FA, Loser DA, Chalmers AJ. 2008. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int. J. Radiat. Oncol. Biol. Phys. 72:1188-97
44. Powell C, Mikropoulos C, Kaye SB, et al. 2010. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat. Rev. 36:566-75
45. Hickman MJ, Samson LD. 1999. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc. Natl. Acad. Sci. USA 96:10764-69
46. Roos W, Baumgartner M, Kaina B. 2004. Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1. Oncogene 23:359-67
47. Karran P, Stephenson C. 1990. Mismatch binding proteins and tolerance to alkylating agents in human cells. Mutat. Res. 236:269-75
48. Pepponi R, Marra G, Fuggetta MP, et al. 2003. The effect of O6-Alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1, 3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J. Pharmacol. Exp. Ther. 304:661-68
49. Shinsato Y, Furukawa T, Yunoue S, et al. 2013. Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. Oncotarget 4:2261-70
50. von Bueren AO, Bacolod MD, Hagel C, et al. 2012. Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours. Br. J. Cancer 107:1399-408
51. Pegg AE, Dolan ME, Moschel RC. 1995. Structure, function, and inhibition of O6-Alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid. Res. Mol. Biol. 51:167-223
52. Pegg AE. 1990. Mammalian O6-Alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 50:6119-29
53. Zaidi NH, Liu L, Gerson SL. 1996. Quantitative immunohistochemical estimates of O6-Alkylguanine-DNA alkyltransferase expression in normal and malignant human colon. Clin. Cancer Res. 2:577-84
54. Esteller M, Hamilton SR, Burger PC, et al. 1999. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 59:793-97
55. Hegi ME, Diserens AC, Gorlia T, et al. 2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352:997-1003
56. Kaina B, Margison GP, Christmann M. 2010. Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell. Mol. Life Sci. 67:3663-81
57. Friedman HS, Kokkinakis DM, Pluda J, et al. 1998. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J. Clin. Oncol. 16:3570-75
58. Rabik CA, Njoku MC, Dolan ME. 2006. Inactivation of O6-Alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat. Rev. 32:261-76
59. Cerchia L, de Franciscis V. 2010. Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol. 28:517-25
60. Trivedi RN, Wang XH, Jelezcova E, et al. 2008. Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide. Mol. Pharmacol. 74:505-16
61. Cerda SR, Turk PW, Thor AD, Weitzman SA. 1998. Altered expression of the DNA repair protein, N-methylpurine-DNA glycosylase (MPG) in breast cancer. FEBS Lett. 431:12-18
62. Kim NK, Ahn JY, Song J, et al. 2003. Expression of the DNA repair enzyme, N-methylpurine-DNA glycosylase (MPG) in astrocytic tumors. Anticancer Res. 23:1417-23
63. Abbotts R, Madhusudan S. 2010. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat. Rev. 36:425-35
64. Al-Attar A, Gossage L, Fareed KR, et al. 2010. Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br. J. Cancer 102:704-9
65. Zaremba T, Ketzer P, Cole M, et al. 2009. Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines. Br. J. Cancer 101:256-62
66. Bauer M, Goldstein M, Heylmann D, Kaina B. 2012. Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant. PLOS ONE 7:e39956
67. Tentori L, Ricci-Vitiani L, Muzi A, et al. 2014. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. BMC Cancer 14:151
68. Taverna P, Liu L, Hwang HS, et al. 2001. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat. Res. 485:269-81
69. Gordon MS, Rosen LS, Mendelson D, et al. 2013. A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest. New Drugs 31:714-23
70. Del Rowe JD, Bello J, Mitnick R, et al. 1999. Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. Int. J. Radiat. Oncol. Biol. Phys. 43:89-93
71. Plummer R, Jones C, Middleton M, et al. 2008. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14:7917-23
72. Plo I, Liao ZY, Barcelo JM, et al. 2003. Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair 2:1087-100
73. Smith LM, Willmore E, AustinCA, Curtin NJ. 2005. The novel poly(ADP-ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence ofDNAstrand breaks. Clin. Cancer Res. 11:8449-57
74. Kummar S, Chen A, Ji J, et al. 2011. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 71:5626-34
75. Holm C, Covey JM, Kerrigan D, Pommier Y. 1989. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 49:6365-68
76. Strumberg D, Pilon AA, Smith M, et al. 2000. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5-phosphorylated DNA double-strand breaks by replication runoff. Mol. Cell. Biol. 20:3977-87
77. Fedier A, Steiner RA, Schwarz VA, et al. 2003. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22:1169-73
78. Davidson D, Coulombe Y, Martinez-Marignac VL, et al. 2012. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest. New Drugs 30:1248-56
79. Ma CX, Ellis MJ, Petroni GR, et al. 2013. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res. Treat. 137:483-92
80. Willmore E, de Caux S, Sunter NJ, et al. 2004. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 103:4659-65
81. Tamaichi H, Sato M, Porter AC, et al. 2013. Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor. Cancer Sci. 104:178-84
82. Goldstein M, Roos WP, Kaina B. 2008. Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling. Toxicol. Appl. Pharmacol. 229:20-32
83. Tong WP, Kirk MC, Ludlum DB. 1982. Formation of the cross-link 1-[N3-deoxycytidyl], 2-[N1-deoxyguanosinyl]-ethane in DNA treated with N, N-bis(2-chloroethyl)-N-nitrosourea. Cancer Res. 42:3102-5
84. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, et al. 1985. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24:707-13
85. Damia G, Imperatori L, Stefanini M, D'Incalci M. 1996. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int. J. Cancer 66:779-83
86. Usanova S, Piee-Staffa A, Sied U, et al. 2010. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol. Cancer 9:248
87. Horwich A, Shipley J, Huddart R. 2006. Testicular germ-cell cancer. Lancet 367:754-65
88. Kuschal C, Thoms KM, Boeckmann L, et al. 2011. Cyclosporin A inhibits nucleotide excision repair via downregulation of the xeroderma pigmentosum groupAandGproteins, which is mediated by calcineurin inhibition. Exp. Dermatol. 20:795-99
89. Prewett M, Deevi DS, Bassi R, et al. 2007. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin. Cancer Res. 13:7432-40
90. Alekseev S, AyadiM, Brino L, et al. 2014. A small molecule screen identifies an inhibitor of DNA repair inducing the degradation of TFIIH and the chemosensitization of tumor cells to platinum. Chem. Biol. 21(3):398-407
91. VolleberghMA, Lips EH, Nederlof PM, et al. 2011. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann. Oncol. 22:1561-70
92. Swisher EM, SakaiW, Karlan BY, et al. 2008. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68:2581-86
93. Kim H, D'Andrea AD. 2012. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 26:1393-408
94. Taniguchi T, TischkowitzM, AmezianeN, et al. 2003. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9:568-74
95. Marsit CJ, Liu M, Nelson HH, et al. 2004. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23:1000-4
96. Farmer H, McCabe N, Lord CJ, et al. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-21
97. Bryant HE, Schultz N, Thomas HD, et al. 2005. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-17
98. Edwards SL, Brough R, Lord CJ, et al. 2008. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111-15
99. Bouwman P, Aly A, Escandell JM, et al. 2010. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17:688-95
100. Patel AG, Sarkaria JN, Kaufmann SH. 2011. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc. Natl. Acad. Sci. USA 108:3406-11